Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report

Mayank Rao; Meenakshi Bhattacharjee; Scott Shepard; Sigmund Hsu

doi:10.18632/oncotarget.28428

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report

PDF | How to cite

Oncotarget. 2023; 14:438-438. https://doi.org/10.18632/oncotarget.28428

Metrics: PDF 792 views | ?

Mayank Rao¹, Meenakshi Bhattacharjee², Scott Shepard³ and Sigmund Hsu¹

¹The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
²Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
³Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA

Published: May 10, 2023

Copyright: © 2023 Rao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Informed patient consent was obtained.

Original article: Oncotarget. 2019; 10:6038-6042. DOI: https://doi.org/10.18632/oncotarget.27203.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28428

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report